Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Currently there are no approved therapies for lung transplant recipients in the United States
(US). Treatment with CIS following lung transplantation has previously been demonstrated to
result in a clinically meaningful improvement in survival and chronic rejection-free survival
compared to placebo, but additional data supporting its use is needed prior to Food and Drug
Administration (FDA) approval. This treatment use protocol is a mechanism for providing
eligible lung transplant recipients early access to CIS in advance of FDA approval.